文献速递流行病学与生物统计真实世界研究与卫生经济

多药联用定义在心血管领域存在低估:应基于活性成分计数

Polypharmacy, defined as taking five or more drugs, is inadequate in the cardiovascular setting.
PubMed 文献 · J Clin Epidemiol · 2018-05-16

该研究基于 CoLaus 队列 880 名基线服用心血管药物的参与者进行为期 10 年的前瞻性随访,比较按药物数量定义的多药联用与按药理活性成分数量定义的多活性成分用药之间的差异。结果显示,按药物数量定义会低估实际服用五种及以上药理活性心血管成分的人数,作者建议多药联用应基于药理活性成分数量而非药物数量。

要点

  • 按药物数量定义多药联用会低估实际活性成分暴露。
  • 随访中多活性成分用药比例接近 17.6%,高于多药联用的 11.9%。
  • 评估心血管用药负担时应优先按药理活性成分计数。

核心结论

  • 在服用心血管药物的人群中,按药物数量定义的多药联用会低估服用五种及以上药理活性药物者的比例。
  • 作者建议多药联用不应再基于药物数量,而应基于药理活性成分数量。

研究设计与样本

  • 前瞻性 10 年随访研究,纳入 CoLaus 研究中基线服用心血管药物的 880 名参与者。
  • 多药联用定义为使用五种及以上心血管药物,多活性成分用药定义为使用五种及以上药理活性心血管成分。

主要发现

  • 多药联用患病率从基线的 1.4%(95%CI 0.7-2.4)上升至随访时的 11.9%(95%CI 9.9-14.3)。
  • 多活性成分用药患病率从基线的 2.4%(95%CI 1.5-3.6)上升至随访时的近 17.6%(95%CI 15.2-20.3)。
  • 复方药物使用比例从基线的 15.7%(95%CI 13.3-18.3)升至随访时的 25.9%(95%CI 23-28.9)。
  • 三联复方使用比例从基线的 0.1%(95%CI 0.0-0.6)升至随访时的 2.3%(95%CI 1.4-3.5)。
  • 基线时 21 名多活性成分用药者中有 9 名未被判定为多药联用,随访时 155 名中有 50 名未被判定。

临床怎么用

  • 临床与科研中评估心血管患者用药负担时,宜同时统计药理活性成分数量以识别被低估的多重用药者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: By how much polypharmacy (defined by number of drugs) differs from polyactive ingredient use (defined by the number of pharmacologically active ingredients) has not been assessed. OBJECTIVES: To compare the extent of polypharmacy vs. polyactive ingredients among patients taking cardiovascular (CV) medicines. METHODS: Prospective, 10-year follow-up study conducted among 880 participants of the CoLaus study taking CV drugs at baseline. Polypharmacy was defined as the use of five or more CV medicines; polyactive ingredient use was defined as the use of five or more pharmacologically active CV ingredients. RESULTS: The prevalence of polypharmacy increased from 1.4% (0.7-2.4) (prevalence rate [95% confidence interval]) at baseline to 11.9% (9.9-14.3) at follow-up, and the prevalence of polyactive ingredients increased from 2.4% (1.5-3.6) at baseline to almost 17.6% (15.2-20.3) at follow-up. The prevalence of combination drugs increased from 15.7% (13.3-18.3) at baseline to 25.9% (23-28.9) at follow-up, and the prevalence of three-component combination use increased from 0.1% (0.0-0.6) at baseline to 2.3% (1.4-3.5) at follow-up. At baseline, nine of 21 participants on polyactive ingredients were not considered as being on polypharmacy; at follow-up, the rate was 50 of 155 participants. CONCLUSION: Among individuals taking CV drugs, polypharmacy as defined by the number of drugs underestimates the prevalence of individuals taking five or more pharmacologically active drugs. Polypharmacy should no longer be based on the number of drugs but on the number of pharmacologically active drugs.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Abolhassani N, Marques-Vidal P. Polypharmacy, defined as taking five or more drugs, is inadequate in the cardiovascular setting. J Clin Epidemiol. 2018. PMID: 29777797. doi:10.1016/j.jclinepi.2018.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。